ATE161041T1 - Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten - Google Patents

Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten

Info

Publication number
ATE161041T1
ATE161041T1 AT90309120T AT90309120T ATE161041T1 AT E161041 T1 ATE161041 T1 AT E161041T1 AT 90309120 T AT90309120 T AT 90309120T AT 90309120 T AT90309120 T AT 90309120T AT E161041 T1 ATE161041 T1 AT E161041T1
Authority
AT
Austria
Prior art keywords
hcv
lymphocytes
cultivation
cell lines
directed
Prior art date
Application number
AT90309120T
Other languages
English (en)
Inventor
Amy J Weiner
Kathelyn S Steimer
Michael Houghton
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23576300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE161041(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE161041T1 publication Critical patent/ATE161041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Details Of Audible-Bandwidth Transducers (AREA)
  • Telephone Function (AREA)
  • Measurement Of Mechanical Vibrations Or Ultrasonic Waves (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT90309120T 1989-08-25 1990-08-21 Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten ATE161041T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39866789A 1989-08-25 1989-08-25

Publications (1)

Publication Number Publication Date
ATE161041T1 true ATE161041T1 (de) 1997-12-15

Family

ID=23576300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90309120T ATE161041T1 (de) 1989-08-25 1990-08-21 Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten

Country Status (12)

Country Link
EP (1) EP0414475B1 (de)
JP (3) JPH05502156A (de)
AT (1) ATE161041T1 (de)
AU (1) AU655156B2 (de)
CA (1) CA2064705C (de)
DE (1) DE69031791T2 (de)
DK (1) DK0414475T3 (de)
ES (1) ES2110411T3 (de)
GR (1) GR3026114T3 (de)
IE (1) IE903097A1 (de)
PT (1) PT95093B (de)
WO (1) WO1991002820A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
GR1001261B (el) 1989-12-18 1993-06-30 Wellcome Found Ιϊκός παράγων.
AU7672991A (en) * 1990-04-03 1991-10-30 Southwest Foundation For Biomedical Research Purified hcv and hcv proteins and peptides
AU7679491A (en) * 1990-04-04 1991-10-30 Protos, Inc. Hepatitis c virus protease inhibitors
DE69132332T2 (de) * 1990-04-06 2000-11-30 Genelabs Technologies, Inc. Hepatitis c-virus-epitope
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
CA2065690A1 (en) * 1991-04-10 1992-10-11 Hiroaki Okamoto Non-a, non-b hepatitis related antigens, detection systems, polynucleotides and polypeptides
US5428145A (en) * 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
EP0610436B9 (de) 1991-11-21 2003-03-26 Common Services Agency Detektion des Hepatis-C Virus.
US5552310A (en) * 1992-06-12 1996-09-03 Hiroshi Yoshikura Replication of hepatitis C virus genome and identification of virus having high infectivity
WO1994025064A1 (en) * 1993-05-04 1994-11-10 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMANSERVIC ES Hepatitis c virus cell propagation and related methods
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5851758A (en) * 1995-10-25 1998-12-22 Childrens Research Institute Cytopathic replication of hepatitis C virus in a new cell line
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
EP0852626B1 (de) * 1996-01-29 2002-04-03 Virologic, Inc. Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
AT407256B (de) * 1998-06-24 2001-02-26 Immuno Ag Hepatitis c-virus positive endometriale zelllinie
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
JP5175417B2 (ja) 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
GB201119011D0 (en) * 2011-11-03 2011-12-14 Queen Mary Innovation Ltd Method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
EP0071640B1 (de) * 1981-02-11 1986-06-04 Connaught Laboratories Incorporated Nicht-a, nicht-b hepatitisvirus
EP0261233A4 (de) * 1986-04-01 1988-08-29 Genelabs Inc Immortalisierte virus-spezifische gewebezellen.
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン

Also Published As

Publication number Publication date
JP2004049235A (ja) 2004-02-19
EP0414475A1 (de) 1991-02-27
DE69031791D1 (de) 1998-01-22
AU655156B2 (en) 1994-12-08
IE903097A1 (en) 1991-02-27
DE69031791T2 (de) 1998-04-02
JP2001314192A (ja) 2001-11-13
AU6344990A (en) 1991-04-03
DK0414475T3 (da) 1998-02-09
CA2064705A1 (en) 1991-02-26
WO1991002820A1 (en) 1991-03-07
GR3026114T3 (en) 1998-05-29
PT95093A (pt) 1991-05-22
CA2064705C (en) 1999-04-06
ES2110411T3 (es) 1998-02-16
JPH05502156A (ja) 1993-04-22
EP0414475B1 (de) 1997-12-10
PT95093B (pt) 1997-11-28

Similar Documents

Publication Publication Date Title
ATE161041T1 (de) Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
YU45871B (sh) Polipeptid sa humanim imunointerferonskim (ifn-gama) svojstvima
DE3587268D1 (de) Verfahren zur isolierung des mycobakteriellen antigens-a60 und die verwendung dieses antigens zur herstellung von immunologischen reagenzien und in immunologischen testverfahren.
ATE301707T1 (de) Aus einer mit einem stamm von multiple-sklerosis- virus infizierten zellinie hergestelltes biologisches virusmaterial
ATE2442T1 (de) Verfahren zur herstellung von interferon und dabei verwendete kulturmediumzusammensetzung.
ATE8409T1 (de) Verfahren zum vermehren menschlicher hepatitis-a viren in einer zellkultur in vitro.
ATE530657T1 (de) Verfahren zur herstellung von zellinien mit latentem immunschwächevirus
EP0278487A3 (de) Verfahren zur Inaktivierung hüllhaltiger Viren in mittels einer Zelle in vitro hergestellten Protein-Präparationen
ATA292889A (de) Verfahren zur herstellung von fsme-virus-antigen
DE69111406D1 (de) DNA-Isolierungsverfahren.
DE69322227D1 (de) Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind
ATE31733T1 (de) Verfahren zur herstellung von hybridisierungssonden.
DE3882154D1 (de) Verfahren zur herstellung des pres 1/s2/s-hepatitis-b-antigens aus hefe.
ATE13910T1 (de) Verfahren zur zuechtung von humanen fibroblasten und fibroblastenartigen zellen.
DE3650468D1 (de) Methoden zur Verwendung von an humanen Klasse-II-Histokompatibilitätsantigenen mangelnden Zellinien
DE3884777D1 (de) Verfahren zur Herstellung von Pregneno-Oxazolinen.
DE69331696D1 (de) Stabilisierte kultur von zellularaggregaten und verfahren zur entwicklung von embryos aus proembryogenen stämmen für die regeneration von weinreben
DE69012903D1 (de) Verfahren zur herstellung und reinigung von hepatitis b-impfstoff.
ATE51026T1 (de) Hybridzellen, die ein hepatitis-b-virus-antigen produzieren, aus hepatocyten und errichteten affenzellen, verfahren zur herstellung dieser hybridzellen und verwendung derselben zur herstellung der obenerwaehnten antigens.
ATE30244T1 (de) Verfahren und vorrichtung zur kultivierung von mikroorganismen.
ATE49777T1 (de) Verfahren zur zuechtung von hepatozyten und cozuechtung von hepatozyten und von behandelten epithelien leberzellen.
DE69311552D1 (de) Verfahren zur vermehrung von infektionsagenzien in "in-vitro"-diagnostik mit mykoplasma enthaltenden zellenkulturen
DD138327A1 (de) Verfahren zur kultivierung von mikroorganismen und deren abtrennung aus dem kulturmedium
ATA126884A (de) Verfahren zur herstellung von kelchartigen glasgegenstaenden und vorrichtung zur durchfuehrung dieses verfahrens
ATA261884A (de) Verfahren zur effektivierung der erzeugung von proteinen in bakterien der gattung bacillus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time